MedTrace Logo

A Four-Way Cross-Over Study To Compare The Plasma Concentrations Of PF-02413873 After Oral Administration Of Several Doses As Suspension And As Tablets.

NCT00857571 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-12-07

No results posted yet for this study

Summary

The study compares the plasma concentrations of PF-02413873 after administration of several doses as suspension and as tablets

Conditions

  • Healthy

Interventions

DRUG

150 mg Suspension

Single oral dose of 150 mg of PF-02413873 suspension

DRUG

30 mg Suspension

Single oral dose of 30 mg of PF-02413873 suspension

DRUG

400 mg Suspension

Single oral dose of 400 mg of PF-02413873 suspension

DRUG

5 mg Suspension

Single oral dose of 5 mg of PF-02413873 suspension

DRUG

750 mg Suspension

Single oral dose of 750 mg of PF-02413873 suspension

DRUG

150 mg Tablet

Single oral dose of 150 mg of PF-02413873 tablets

DRUG

30 mg Tablet

Single oral dose of 30 mg of PF-02413873 tablets

DRUG

400 mg Tablet

Single oral dose of 400 mg of PF-02413873 tablets

DRUG

5 mg Tablet

Single oral dose of 5 mg of PF-02413873 tablets

DRUG

750 mg Tablet

Single oral dose of 750 mg of PF-02413873 tablets

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00857571 on ClinicalTrials.gov